Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-Dose, Double-Blind, Randomized Multi-Center Trial - POTENT I

Trial Profile

Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-Dose, Double-Blind, Randomized Multi-Center Trial - POTENT I

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vardenafil (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms POTENT-1
  • Sponsors Bayer; Bayer HealthCare

Most Recent Events

  • 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
  • 15 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
  • 13 Feb 2013 Planned number of patients changed from 350 to 362 as reported by German Clinical Trials Register.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top